Tempest Therapeutics (NASDAQ:TPST) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tempest Therapeutics (NASDAQ:TPST) from a sell rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Friday, October 9th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce”.

Tempest Therapeutics Trading Down 0.2%

NASDAQ TPST opened at $0.51 on Friday. The stock has a 50-day simple moving average of $0.86 and a two-hundred day simple moving average of $1.56. Tempest Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $11.13.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.04). On average, research analysts anticipate that Tempest Therapeutics will post -0.83 earnings per share for the current year.

Institutional Trading of Tempest Therapeutics

A hedge fund recently bought a new position in Tempest Therapeutics stock. Squarepoint Ops LLC acquired a new stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 30,900 shares of the company’s stock, valued at approximately $34,000. Squarepoint Ops LLC owned approximately 0.19% of Tempest Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s approach is designed to address both tumor cells and the immune environment surrounding them, with the goal of stimulating antitumor immune responses and improving the effectiveness of cancer treatment.

Tempest’s pipeline includes TPST-1120, an orally administered, selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR?). The company has evaluated TPST-1120 in clinical studies involving advanced solid tumors, including hepatocellular carcinoma, and has investigated its use in combination with other cancer therapies.